PMID- 27357359
OWN - NLM
STAT- MEDLINE
DCOM- 20180409
LR  - 20220408
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 37
IP  - 38
DP  - 2016 Oct 7
TI  - Two-year outcomes of patients with newly diagnosed atrial fibrillation: results 
      from GARFIELD-AF.
PG  - 2882-2889
AB  - AIMS: The relationship between outcomes and time after diagnosis for patients 
      with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond 
      the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global 
      observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 
      162 patients prospectively enrolled in GARFIELD-AF were analysed in light of 
      baseline characteristics, risk profiles for stroke/systemic embolism (SE), and 
      antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 
      43.8% were women, and the mean CHA(2)DS(2)-VASc score was 3.3 (1.6); 60.8% of 
      patients were prescribed anticoagulant therapy with/without antiplatelet (AP) 
      therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year 
      follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a 
      rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 
      (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events 
      were highest during the first 4 months. Congestive heart failure, acute coronary 
      syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and 
      infection/sepsis accounted for 65% of all known causes of death and strokes for 
      <10%. Anticoagulant treatment was associated with a 35% lower risk of death. 
      CONCLUSION: The most frequent of the three major outcome measures was death, 
      whose most common causes are not known to be significantly influenced by 
      anticoagulation. This suggests that a more comprehensive approach to the 
      management of NVAF may be needed to improve outcome. This could include, in 
      addition to anticoagulation, interventions targeting modifiable, cause-specific 
      risk factors for death. CLINICAL TRIAL REGISTRATION: 
      http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
CI  - (c) The Author 2016. Published by Oxford University Press on behalf of the European 
      Society of Cardiology.
FAU - Bassand, Jean-Pierre
AU  - Bassand JP
AD  - University of Besancon, Besancon, France jpbassand@tri-london.ac.uk 
      jpbassand@orange.fr.
AD  - Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, London SW3 
      6LR, UK.
FAU - Accetta, Gabriele
AU  - Accetta G
AD  - Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, London SW3 
      6LR, UK.
FAU - Camm, Alan John
AU  - Camm AJ
AD  - St George's University of London, London, UK.
FAU - Cools, Frank
AU  - Cools F
AD  - AZ Klina, Brasschaat, Belgium.
FAU - Fitzmaurice, David A
AU  - Fitzmaurice DA
AD  - University of Birmingham, Edgbaston, Birmingham, UK.
FAU - Fox, Keith A A
AU  - Fox KA
AD  - University of Edinburgh, Edinburgh, UK.
FAU - Goldhaber, Samuel Z
AU  - Goldhaber SZ
AD  - Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
FAU - Goto, Shinya
AU  - Goto S
AD  - Tokai University, Kanagawa, Japan.
FAU - Haas, Sylvia
AU  - Haas S
AD  - Formerly Technical University of Munich, Munich, Germany.
FAU - Hacke, Werner
AU  - Hacke W
AD  - University of Heidelberg, Heidelberg, Germany.
FAU - Kayani, Gloria
AU  - Kayani G
AD  - Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, London SW3 
      6LR, UK.
FAU - Mantovani, Lorenzo G
AU  - Mantovani LG
AD  - University of Milano-Bicocca, Milan, Italy.
FAU - Misselwitz, Frank
AU  - Misselwitz F
AD  - Bayer HealthCare Pharmaceuticals, Berlin, Germany.
FAU - Ten Cate, Hugo
AU  - Ten Cate H
AD  - Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
FAU - Turpie, Alexander G G
AU  - Turpie AG
AD  - McMaster University, Hamilton, Canada.
FAU - Verheugt, Freek W A
AU  - Verheugt FW
AD  - University Hospital, Nijmegen.
AD  - Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
FAU - Kakkar, Ajay K
AU  - Kakkar AK
AD  - Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, London SW3 
      6LR, UK.
AD  - University College London, London, UK.
CN  - GARFIELD-AF Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT01090362
PT  - Journal Article
PT  - Observational Study
DEP - 20160629
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Anticoagulants)
SB  - IM
CIN - Eur Heart J. 2016 Oct 7;37(38):2890-2892. PMID: 27436866
MH  - Aged
MH  - Anticoagulants
MH  - *Atrial Fibrillation
MH  - Female
MH  - Hemorrhage
MH  - Humans
MH  - Male
MH  - Risk Factors
MH  - Stroke
PMC - PMC5070447
OTO - NOTNLM
OT  - *Anticoagulation
OT  - *Atrial fibrillation
OT  - *Bleeding
OT  - *Stroke
OT  - *Stroke prevention
EDAT- 2016/07/01 06:00
MHDA- 2018/04/10 06:00
PMCR- 2016/06/29
CRDT- 2016/07/01 06:00
PHST- 2015/10/27 00:00 [received]
PHST- 2016/03/30 00:00 [revised]
PHST- 2016/04/29 00:00 [accepted]
PHST- 2016/07/01 06:00 [pubmed]
PHST- 2018/04/10 06:00 [medline]
PHST- 2016/07/01 06:00 [entrez]
PHST- 2016/06/29 00:00 [pmc-release]
AID - ehw233 [pii]
AID - 10.1093/eurheartj/ehw233 [doi]
PST - ppublish
SO  - Eur Heart J. 2016 Oct 7;37(38):2882-2889. doi: 10.1093/eurheartj/ehw233. Epub 
      2016 Jun 29.